 BioMarin Pharmaceutical Inc NASDAQ: BMRN has announced new data from open-label Phase 12 trial of valoctocogene roxaparvovec, an investigational gene therapy candidate for severe hemophilia A. Data were presented at the International Society on Thrombosis and Haemostasis ISTH 2021 Virtual Congress. 